Leveraging the inhibitory effects of metformin on gluconeogenesis alongside the targeted inhibition of IGF1R and FAK pathways may offer a dual-pronged approach to tackling the intricate molecular landscape of HCC. Here, PTK2 is linked to hepatocellular carcinoma.